Literature DB >> 17584963

Attenuation of apoptosis by chromogranin A-induced Akt and survivin pathways in prostate cancer cells.

Junyang Gong1, JuneGoo Lee, Horiguchi Akio, Peter N Schlegel, Ruoqian Shen.   

Abstract

Multiple studies indicate that neuroendocrine (NE) differentiation in prostate cancer (PC) contributes to androgen-independent progression. Levels of chromogranin A (CgA), which is produced by NE cells, are increased in advanced PC. However, the mechanism by which high levels of circulating CgA contribute to PC progression is unknown. To examine the effects of CgA on PC cells, we first performed proliferation assays in the presence of recombinant CgA (rCgA) in LNCaP and C4-2 PC cells, and found that rCgA increased cell proliferation in a dose and time-dependent manner. NE differentiated PC cells, also overexpress the antiapoptosis protein survivin. Therefore, we examined survivin expression in the presence of CgA in PC cells. Western blot analysis showed that survivin was significantly increased by rCgA and inhibited by an anti-CgA antibody in both LNCaP and C4-2 cells. Survivin expression is believed to be regulated by PI3K/Akt pathway. We next assessed the phosphorylation status of Akt and found that Akt phosphorylation was increased by treatment with rCgA. To determine whether Akt phosphorylation is necessary for rCgA-induced survivin expression, we examined the effects of Akt, MAPK kinase, and protein kinase C inhibitors on CgA-induced survivin expression, and found that survivin expression was reduced in the presence of Akt inhibitors, but not MAPK kinase or protein kinase C inhibitors. Furthermore, in the presence of an Akt inhibitor or small interfering RNA of survivin, CgA-enhanced proliferation of C4-2 and LNCaP cells significantly decreased. Together, our results demonstrate that CgA can increase PC cell survival through Akt-mediated survivin up-regulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584963     DOI: 10.1210/en.2006-1748

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Understanding the mechanism underlying the acquisition of radioresistance in human prostate cancer cells.

Authors:  Kosho Murata; Ryo Saga; Satoru Monzen; Echi Tsuruga; Kazuki Hasegawa; Yoichiro Hosokawa
Journal:  Oncol Lett       Date:  2019-04-05       Impact factor: 2.967

Review 2.  EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

Authors:  Rama Soundararajan; Anurag N Paranjape; Sankar Maity; Ana Aparicio; Sendurai A Mani
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-07-05       Impact factor: 10.680

3.  Does valproic acid induce neuroendocrine differentiation in prostate cancer?

Authors:  Abhinav Sidana; Muwen Wang; Wasim H Chowdhury; Antoun Toubaji; Shabana Shabbeer; George Netto; Michael Carducci; Shawn E Lupold; Ronald Rodriguez
Journal:  J Biomed Biotechnol       Date:  2010-10-25

4.  Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells.

Authors:  June G Lee; Rong Zheng; Jennifer M McCafferty-Cepero; Kerry L Burnstein; David M Nanus; Ruoqian Shen
Journal:  Mol Carcinog       Date:  2009-02       Impact factor: 4.784

5.  Plasmid-based Survivin shRNA and GRIM-19 carried by attenuated Salmonella suppresses tumor cell growth.

Authors:  Yan-Bo Liu; Ling Zhang; Ya-Xiong Guo; Li-Fang Gao; Xi-Chun Liu; Li-Juan Zhao; Bao-Feng Guo; Li-Jing Zhao; Xue-Jian Zhao; De-Qi Xu
Journal:  Asian J Androl       Date:  2012-05-14       Impact factor: 3.285

6.  [Infiltrating mast cells promote neuroendocrine differentiation and increase docetaxel resistance of prostate cancer cells by up-regulating p21].

Authors:  Yi-Hong Ou; Yao-Dong Jiang; Qi Li; Yong-Jiang Zhuang; Qiang Dang; Wan-Long Tan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-06-20

Review 7.  Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.

Authors:  Chang-Deng Hu; Richard Choo; Jiaoti Huang
Journal:  Front Oncol       Date:  2015-04-14       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.